Medco hires FDA genomics expert
Executive Summary
Felix Frueh joins Medco as VP-R&D, personalized medicine. He had been associate director for genomics in the FDA's Office of Clinical Pharmacology since 2004. While at the agency, Frueh was responsible for developing policy on pharmacogenomics. He also chaired FDA's Interdisciplinary Pharmacogenomics Review Group. In the new position at Medco, he will advance research in genetic testing aimed at improving the precision of pharmacy care and will develop the firm's Personalized Medicine Research Center, under construction in Whitestown, Ind. Medco currently is collaborating with the Mayo Clinic and Lab Corp. on genetic research on improving treatment with warfarin and tamoxifen (1"The Pink Sheet," Nov. 26, 2007, p. 11)
You may also be interested in...
Warfarin Dosing Issues Emerge In Early Results From Medco/Mayo Research
Nearly three-fourths of early patient participants in a warfarin research project appear to need non-standard dosing of the drug based on genetic screening, Medco reported during its analyst day presentation Nov. 16
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.